Jump to start of content

ABIM call wait times may be longer than usual Expand/Collapse the ABIM alert.

Due to high volume, ABIM call wait times may be longer than usual. We know how busy you are, so we apologize for any inconvenience this may cause. You can always send us a message at abim.org/contact.

Coronavirus Updates Expand/Collapse the ABIM alert.

At ABIM we are actively monitoring the ongoing spread of coronavirus (COVID-19) and will post regular updates about any changes to scheduled assessments.
Scheduled for an assessment this year? ABIM is working with Pearson VUE to ensure your safety throughout your exam day. Learn more about what to expect at test centers.
Please follow the United States Centers for Disease Control and Prevention (CDC) for the most up-to-date information on the virus.

Breadcrumb trail:

Rheumatology Board

Expand All | Collapse All

Salahuddin Kazi, MD, Chair

Salahuddin Kazi, MDDr. Kazi, a board certified internist and rheumatologist, is the Vice Chair of Education for the Department of Internal Medicine and a Professor of Medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center in Dallas, Texas. He is also the Director of the Internal Medicine Residency Training Program at UT Southwestern. Dr. Kazi is the Chair of the American Board of Internal Medicine Rheumatology Board. Dr. Kazi previously served as the Chair of the Registries and Health Information Technology Committee of the American College of Rheumatology overseeing the development of the RISE registry. Dr. Kazi continues to lead efforts in rheumatology to promote improvement in the delivery of healthcare through the principles of co-production.

Dr. Kazi earned his medical degree from Dow Medical College in Karachi, Pakistan, and completed his residency, chief residency and fellowship in rheumatology at the University of Texas Health Science Center in Houston.

As of February 2019, Dr. Kazi reported the following external relationships:

Dr. Kazi serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Arthritis Foundation, serving as a consultant, with funding paid to the UT Southwestern Medical Center.

Susan K. Chrostowski, DNP, APRN, ANP-C

Susan K. Chrostowski, DNP, APRN, ANP-CDr. Susan Chrostowski is an Assistant Clinical Professor at Texas Woman's University in Dallas, Texas where she teaches in the graduate nursing program. Dr. Chrostowski earned her Bachelor of Science in nursing degree at Texas Woman's University in Denton, Texas. She went on to earn a Master of Science degree in nursing, and Doctor of Nursing Practice degree at Texas Woman's University in Dallas, Texas. For her doctoral program, she conducted a clinical research study on assessment instruments on fibromyalgia disease activity and presented those results at the American College of Rheumatology Annual Scientific Meeting in San Francisco, CA in 2015.

Dr. Chrostowski is certified as an Adult Health nurse practitioner through the American Academy of Nurse Practitioners certification board and has been practicing exclusively in rheumatology since 2005. Dr. Chrostowski serves as a member of the American Board of Internal Medicine Rheumatology Board. She has served on several national committees with the Association of Rheumatology Professionals organization. In addition to podium and poster presentations at local and national conferences on rheumatology and geriatric nursing practice, Dr. Chrostowski has published several articles related to rheumatology and nursing practice issues.

As of August 2019, Dr. Chrostowski reported no ongoing external relationships.

Atulya A. Deodhar, MD

Atulya A. Deodhar, MDDr. Deodhar, a board certified internist and rheumatologist, is Professor of Medicine and Medical Director of rheumatology clinics at the Division of Arthritis & Rheumatic Diseases in Oregon Health & Science University, Portland. He is a fellow of the American College of Rheumatology (ACR) and the American College of Physicians.

Dr. Deodhar is the past-Chairman of SPARTAN (Spondyloarthritis Research and Treatment Network), an organization of North American rheumatologists dedicated to education and research in the field of axial spondyloarthritis. He serves on the ACR's treatment guidelines subcommittee and has served in the past as a member and Vice Chair of the Annual Meeting Planning Committee and as a member of the Peripheral MRI Task Force. Dr. Deodhar also served on the Association of Rheumatology Health Professionals (ARHP) nominating committee. Additionally, he serves as a member of the American Board of Internal Medicine Rheumatology Board.

Dr. Deodhar is a reviewer for Arthritis & Rheumatology, Annals of the Rheumatic Diseases and Annals of Internal Medicine, among several other journals. His research interests are axial spondyloarthritis and psoriatic arthritis. He has authored three books, more than 150 peer-reviewed articles, several book chapters, and editorials. Dr. Deodhar has been a principal or co-investigator in more than 100 clinical trials, mainly focused on therapies for ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis.

Dr. Deodhar received his bachelor's degree in medicine and surgery and his medical degree from the University of Pune, India. He completed his fellowship in rheumatology at Oregon Health & Science University, and before that, a research fellowship in rheumatology at the Royal Cornwall Hospital, Truro, England. He completed his residency in internal medicine and geriatrics at the Royal Cornwall Hospital, Truro, as well as in the Sassoon General Hospital and King Edward Memorial Hospital, Pune, India. He holds a membership of the Royal College of Physicians, London, England.

As of May 2020, Dr. Deodhar reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to Oregon Health and Science University, from the following companies:

  • Eli Lilly & Co., funding work as Principal Investigator for studies of ixekizumab in the treatment of axial spondyloarthritis, psoriatic arthritis, and ankylosing spondylitis patients who are TNFi inadequate responders; also serves as Principal Investigator for an Oregon chiropractic axial spondyloarthritis study.
  • Novartis, funding work as Principal Investigator for trials of secukinumab in the treatment of non-radiographic axial spondylarthritis and psoriatic arthritis.
  • Pfizer, funding work as Principal Investigator for a trial of tofacoitinibin the treatment of axial spondyloarthritis.
  • UCB, funding work as Principal Investigator for trials of certolizumab and bimekizumab in the treatment of non-radiographic axial spondyloarthritis.

Investigators' meetings for the following companies, with compensation as listed:

  • Eli Lilly and Company, for multiple studies of ixekizumab in axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Novartis, for multiple of secukinumab in non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • UCB, for multiple studies of non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • AbbVie, advising on treatment of axial spondyloarthritis with upadacitinib, receiving reimbursement for travel expenses and honoraria.
  • Boehringer Ingelheim, advising on treatment of axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Bristol-Myers Squibb, advising on treatment of axial spondyloarthritis and non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Eli Lilly and Company, to discuss results of research studies of ixekizumab in psoriatic arthritis, receiving reimbursement for travel expenses and honoraria.
  • GlaxoSmithKline, advising on treatment of axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Novartis, to discuss the clinical trial design for secukinumab in the treatment of non-radiographic axial spondyloarthritis, and to discuss the future of targeted therapies, receiving reimbursement for travel expenses and honoraria.
  • Pfizer, to discuss the ongoing trial of etanercept in non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • UCB, to discuss certolizumab and bimekizumab and the future landscape of treatments for axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation as listed:

  • Eli Lilly and Company, providing advice on a clinical trial protocol for the use of baricitinibin for ankylosing spondylitis, receiving honoraria.
  • Novartis, advising on a study on the axial spondyloarthritis patient journey and consulting on design of a new study, receiving reimbursement for travel expenses and honoraria.
  • Celgene, advising on new drug to treat ankylosing spondylitis, receiving honoraria.

Industry-supported continuing medical education supported by the following companies, with compensation for travel expenses and honoraria:

  • Dr. Deodhar serves as a discussant for Medscape, providing commentary on abstracts presented at the American College of Rheumatology, receiving reimbursement for travel expenses and honoraria.
  • Dr. Deodhar also serves as faculty for educational symposia at PANLAR Congress and Brazilian spondyloarthritis interest group, receiving reimbursement for travel expenses and honoraria from Novartis.
  • Dr. Deodhar also serves as faculty for educational symposia on axial spondyloarthritis and psoriatic arthritis, with continuing medical education credits provided by Oregon Health & Science University and with the symposia organized by SPARTAN and GRAPPA.

Dr. Deodhar serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Rheumatology, Member of Treatment Guidelines Subcommittee, and Core Member, Treatment Guidelines for Axial Spondyloarthritis, and Voting Panel Member, Psoriatic Arthritis Treatment Guidelines, receiving reimbursement for travel expenses.

Dr. Deodhar also reported receiving honoraria and reimbursement for travel expenses from Janssen, Novartis, and Pfizer for preceptorship for medical science liaisons on axial spondyloarthritis and psoriatic arthritis organized by NW Rheumatology and Osteoporosis Institute, Seattle.

Carlos M. Gadea MD

Carlos M. Gadea MDDr. Gadea is a rheumatologist at the University of Alabama at Birmingham (UAB) Medicine Multispecialty Clinic at Baptist Medical Center South in Montgomery, Alabama. As a clinical instructor, he works with internal medicine residents from the UAB-Montgomery Internal Medicine residency program on their rheumatology elective rotation. He is board certified in both Internal Medicine and Rheumatology.

Prior to his work at UAB, Dr. Gadea worked in a small private rheumatology practice in Seaford, Delaware, with two other rheumatologists. Before that, Dr. Gadea practiced in Pittsburgh, Pennsylvania, at the University of Pittsburgh Medical Center (UPMC). As a Clinical Instructor for the UPMC Division of Rheumatology, he worked as a rheumatologist in one of the division’s satellite rheumatology clinics caring for patients, and providing consultation at St. Clair Hospital and UPMC Mercy, where he also worked with internal medicine residents. After fellowship training, he practiced with a private rheumatology group with four other rheumatologists in Virginia Beach, Virginia.

Dr. Gadea is a member of the American Board of Internal Medicine Rheumatology Board.

Dr. Gadea received his bachelor’s degree in biological sciences from Florida International University. He earned his medical degree from Universidad de Ciencias Medicas de Centro America in San Jose, Costa Rica. He completed his internal medicine residency training with the University of Connecticut Primary Care Internal Medicine program in Farmington, Connecticut, and his rheumatology fellowship at the University of Kentucky in Lexington, Kentucky.

As of August 2019, Dr. Gadea reported no external relationships.

Maryah Mansoor, MD

Maryah Mansoor, MD Dr. Mansoor, a board-certified internist and rheumatologist, practices at Christiana Care Hospital Delaware. She is also Clinical Assistant Professor of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, Pennsylvania.

Dr. Mansoor is a member of the American Board of Internal Medicine Rheumatology Board. She also volunteered for standard setting process for ABIM Rheumatology Certification Exam. She is also a Board Member of the Arthritis Foundation Delaware. Dr. Mansoor is involved in the teaching of internal medicine residents at Christiana Care Hospital.

Dr. Mansoor earned her medical degree as a class valedictorian from Aga Khan Medical University in Karachi, Pakistan. She completed her residency in internal medicine at Staten Island University Hospital (North well Health) and fellowship in rheumatology at Sidney Kimmel Medical College at Thomas Jefferson University.

As of August 2019, Dr. Mansoor reported the following external relationships:

Dr. Mansoor serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Arthritis Foundation, Board of Directors, without compensation.

Daniel McGowan

Daniel McGowanIn nearly 50 years in the health care system Daniel McGowan has managed many elements of that system. He has directed health system planning and regulation for the State of Wisconsin, Long Island and New York City. He has served as Vice-President of Long Island Jewish Medical Center, Executive Director of Catholic Charities health and human services on Long Island and as President and Chief Operating Officer of both the Health Insurance Plan of Greater New York and Emblem Health Services Corporation, the largest Medicare Advantage, Medicaid and HMO in New York.

Now retired, Mr. McGowan currently chairs the Primary Care Development Corporation and Hygea Health Holdings Corporation, and is past chair of National Medical Fellowships and the National Board of the Arthritis Foundation. He serves as a member of the American Board of Internal Medicine Rheumatology Board, and was the Arthritis Foundation's representative to the Board of the American College of Rheumatology. He also served as Trustee of Molloy College and the Health Industry Forum of Brandeis University. Frequently teaching the US Health Care System, Health Planning and Regulation at both undergraduate and graduate levels, he has held faculty posts at Governors State University in Illinois, the University of Wisconsin and Long Island University.

Mr. McGowan holds many honors from various organizations, and is a Certified Rehabilitation Counselor, a Rockefeller Fellow and a Licensed Captain by the US Coast Guard.

As of July 2019, Mr. McGowan reported the following ongoing external relationships:

Mr. McGowan serves in significant roles with the following for-profit health care-related company, receiving reimbursement or compensation as listed:

  • Hygea, without compensation.

Mr. McGowan serves in significant roles with the following non-profit health care-related organizations, receiving reimbursement or compensation as listed:

  • Primary Care Development Corporation, without compensation.
  • National Medical Fellowships, without compensation.

Philip Seo, MD

Philip Seo, MD Dr. Seo is the Director of the Johns Hopkins Vasculitis Center and Director of the Johns Hopkins Rheumatology Fellowship Training Program. He is board certified in both Internal Medicine and Rheumatology.

Dr. Seo has served the American College of Rheumatology (ACR) in a variety of capacities, including as a member of the Committee on Training and Workforce, the Annual Meeting Planning Committee, and the In-Training Examination Taskforce. He has served as a Co-Chair of both the ACR In-Training Examination Taskforce and Annual Scientific Meeting Review Course.

He is now serving the ACR as a Co-Chair of the non-ANCA Vasculitis Abstract Selection Committee for the Annual Scientific Meeting. Dr. Seo serves as a member of the American Board of Internal Medicine Rheumatology Board; he is also the Medical Editor of the Rheumatologist, an official publication of the ACR. He is a recipient of a Clinician Scholar Educator Award from the Rheumatology Research Foundation. Dr. Seo is a Medical Consultant for the Vasculitis Foundation, the largest patient support group for the systemic vasculitides in the United States.

Dr. Seo received a bachelor of arts degree in biochemical sciences from Harvard College, a medical degree from Columbia University, and a master in health science degree from the Johns Hopkins Bloomberg School of Public Health. He completed his training in both internal medicine and rheumatology at the Johns Hopkins Hospital, where he also served as an Assistant Chief of Service (Chief Resident).

As of July 2019, Dr. Seo reported the following ongoing external relationships:

Attendance at investigators’ meetings, with compensation for travel expenses and honoraria from the following company

  • Genentech, regarding tocilzumab.

Service on data and safety monitoring boards for the following company, with honoraria:

  • Celgene, for a clinical trial examining the use of apremilast in a pediatric population for the treatment of psoriasis.

Work as an author or editor for following company, with compensation as listed:

  • American College of Rheumatology, receiving compensation as a medical editor for The Rheumatologist. Dr. Seo also received the Clinician Scholar Educator Award.

Mary C. Wasko, MD, MSc

Mary WaskoDr. Wasko is Division Director of Rheumatology for Allegheny Health Network. She is a professor for Temple University, Pittsburgh Campus. She maintains board certification in both Internal Medicine and Rheumatology. Previously, Dr. Wasko served as a rheumatologist and Associate Professor of Medicine at the University of Pittsburgh, Main Campus.

Dr. Wasko served on the American College of Rheumatology Annual Meeting Planning Committee from 2011 to 2014. She has been a frequent lecturer for the Maintenance of Certification Course. Dr. Wasco is a member of the American Board of Internal Medicine Rheumatology Board Exam Committee. She was voted for Best Doctors in Pittsburgh list, 2012 to 2014, as well as voted Best Doctors in America, 2003 to 2014. She has fifteen years of external funding for investigator-initiated clinical research, serving as primary investigator and co-investigator on rheumatoid arthritis-related studies. Her work has resulted in more than 30 publications in peer-reviewed journals, including the New England Journal of Medicine, Arthritis and Rheumatology and the Journal of the American Medical Association.

Dr. Wasko received a bachelor’s degree from Davidson College in North Carolina in 1979. She then received her medical degree from the University of North Carolina, School of Medicine, Chapel Hill in 1983. She further completed a master’s degree in clinical research design and biostatistics from the University of Michigan School of Public Health in 1992.

As of May 2020, Dr. Wasko reported the following ongoing external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the Allegheny Health Network, from the following companies:

  • AbbVie
  • AstraZeneca
  • Amgen
  • Human Genome Sciences
  • GlaxoSmithKline
  • Merck
  • Roche